Lucid Diagnostics Inc. filings document a commercial-stage medical diagnostics issuer focused on esophageal precancer detection, its public-company governance, and its capital structure. Its 8-K reports disclose operating results and business updates for EsoGuard and EsoCheck, Regulation FD communications, completed common stock offerings, shelf registration statement references, proceeds for working capital and general corporate purposes, and related exhibits.
Proxy materials cover annual meeting matters, director elections, board classification, and stockholder voting. Other material-event filings address board appointments, non-employee director compensation arrangements, indemnification agreements, and governance rights associated with holders of the company’s convertible secured promissory notes due 2029.
PALUMBO JOHN R reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. director John R. Palumbo received a grant of 123,000 shares of common stock as a restricted stock award under the company’s 2018 Equity Plan. The award was granted at $0.00 per share and increases his directly held common stock to 338,000 shares.
The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed, meaning Palumbo must remain in the specified service role through that date for the shares to fully vest.
Lapidus Stanley reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. director Stanley Lapidus received a grant of 123,000 shares of common stock as an equity award. The award was granted at no cash cost and increased his directly held shares to 337,392. The shares are restricted stock under the company’s 2018 Equity Plan with a single vesting date of May 20, 2029, and are subject to forfeiture if the required service period is not completed.
Lucid Diagnostics Inc. director James L. Cox reported an equity award of common stock. He acquired 123,000 shares of restricted stock at a grant price of $0.00 per share as a grant, award, or other acquisition under the company’s 2018 Equity Plan. These restricted shares have a single vesting date of May 20, 2029 and are subject to forfeiture if the required service period is not completed. Following this award, Cox directly holds a total of 405,120 shares of Lucid Diagnostics common stock.
Lucid Diagnostics Inc. reported that Chief Financial Officer Dennis M. McGrath acquired 470,000 shares of common stock through a restricted stock grant at a price of $0.00 per share. These shares vest in a single installment on May 20, 2029 and are subject to forfeiture if the required service period is not completed. Following this award, McGrath directly holds 1,813,569 shares of Lucid Diagnostics common stock.
Lucid Diagnostics Inc. reported that President and COO Shaun O'Neil acquired 620,000 shares of common stock through a restricted stock grant under the company’s 2018 Equity Plan. The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this award, O'Neil directly holds 1,446,763 shares of common stock.
Gordon Michael Adam reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. reported that its General Counsel and Secretary, Gordon Michael Adam, received a grant of 300,000 shares of common stock on February 20, 2026. The award is structured as restricted stock that vests in full on May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this grant, Adam directly holds 1,000,000 shares of Lucid Diagnostics common stock.
PAVmed Inc. filed Amendment No. 6 to its Schedule 13D regarding its stake in Lucid Diagnostics Inc.. PAVmed reports beneficial ownership of 38,816,903 shares of Lucid common stock, representing 27.5% of the class, giving it significant influence over shareholder votes.
The filing notes sole voting power over 38,816,903 shares and sole dispositive power over 31,302,444 shares, including voting proxies obtained from other Lucid stockholders and officers. PAVmed also entered an Amendment Agreement granting its noteholder the right to receive 300,000 Lucid shares upon specified future events, subject to a beneficial ownership limitation.
Lucid Diagnostics (LUCD) furnished an update announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025 and a business update. The release was provided as Exhibit 99.1. The information was furnished under Items 2.02 and 7.01 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference unless specifically stated.
Lucid Diagnostics (LUCD) reported Q3 2025 results, highlighting modest revenue and continued investment alongside a formal going concern warning. Revenue was $1.2 million for the quarter and $3.2 million year-to-date, reflecting ongoing early commercialization of EsoGuard testing. Operating loss was $11.8 million in Q3; net loss attributable to common stockholders was $10.4 million, or $0.10 per share.
Cash stood at $47.3 million as of September 30, 2025, with working capital of $23.6 million and operating cash outflows of $33.9 million for the nine months. Management states that substantial doubt exists about the company’s ability to continue as a going concern within one year, absent materially higher reimbursement-driven revenue or additional financing.
To fund operations, Lucid raised capital through equity offerings—$14.9 million (March), $16.2 million (April), and $27.0 million (September)—and has $21.975 million face value of 12% Senior Secured Convertible Notes (fair value $22.3 million; $1.00 conversion price). Common shares issued and outstanding were 130,924,686 as of September 30, 2025; 137,683,002 as of November 7, 2025.
PAVmed Inc. filed Amendment No. 5 to its Schedule 13D on Lucid Diagnostics (LUCD), reporting significant ownership and updated voting arrangements. PAVmed beneficially owns 38,816,903 shares of common stock, representing 28.3% of the class. It reports sole voting power over 38,816,903 shares and sole dispositive power over 31,302,444 shares.
On October 9, 2025, PAVmed entered a new Voting Agreement covering shares representing 3,177,500 votes of common stock and 3,862,911 votes of other capital stock, in addition to prior voting agreements covering 4,336,959 votes held by certain officers. Recent insider-related activity includes restricted stock awards granted on February 20, 2025 to officers (300,000 shares each) and directors (112,800 shares each), and an open-market purchase by a trust controlled by Michael J. Glennon of 129,000 shares at approximately $1.04 per share for an aggregate of $133,782.70. Certain insiders agreed to a 45‑day lockup in connection with the September 10, 2025 underwritten offering.